Clinical trials: Treatment Resistant Depressive Disorder
Treatment-resistant Depression
Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression
Treatment resistant depression (TRD) is a frequent, debilitating condition mostly treated by antidepressants. Repeated magnetic transcranial stimulation (rTMS) has proven adjuvant efficacy in TRD in the acute phase of treatment…
- Trial name
- ACOUSTIM (NCT03701724)
- Testing
- Systematic maintenance rTMS, rTMS course in case of relapse
- Where
- 19 sites in France
- Volunteers
- 119 people
- Sponsor
- Nantes University Hospital
Electroconvulsive Therapy, Intravenous Ketamine
Electroconvulsive Therapy Versus Intravenous Ketamine in Treatment-Resistant Major Depressive Disorder
This study aimed to compare the efficacy, safety, and tolerability of electroconvulsive therapy (ECT) versus intravenous (IV) ketamine in adults with treatment-resistant major depressive disorder (TRD).
- Conditions
- Electroconvulsive Therapy, Intravenous Ketamine, Treatment-Resistant, Major Depressive Disorder
- Trial name
- NCT07526454
- Testing
- Electroconvulsive Therapy, Ketamine
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Tanta University
Treatment Resistant Depression, Depression - Major Depressive Disorder
Characterizing Synaptic Density in Treatment Resistant Depression
The purpose of this study is to better understand how certain brain systems work in people with depression, especially in those whose symptoms have not improved with antidepressant treatments.
- Trial name
- TPET (NCT03537794)
- Testing
- PET scans
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Bipolar Depression
Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic
The current study aims to assess the feasibility, acceptance and clinical outcomes of a practical high-dose LFR protocol, including tapering treatments and symptom-based relapse prevention treatments, in patients with bipolar…
- Trial name
- NCT04427137
- Testing
- MagPro X100 Stimulator, B70 Fluid-Cooled Coil
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- Centre for Addiction and Mental Health
Healthy, Major Depressive Disorder
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome.
- Conditions
- Healthy, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06480201
- Testing
- Ketamine, Saline
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Major Depressive Disorder, Depression
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin
The purpose of this study is to see if one or two doses of psilocybin is more effective in relieving depressive symptoms in patients with treatment-resistant depression (TRD).
- Conditions
- Major Depressive Disorder, Depression, Treatment-Resistant Depression, Mood Disorders
- Trial name
- PSI-1V2 (NCT06341426)
- Testing
- Single Psychedelic Dose Psilocybin, Two Psychedelic Doses Psilocybin
- Where
- 2 sites in Canada
- Volunteers
- 92 people
- Sponsor
- University Health Network, Toronto
Adolescent Depression
Lamotrigine in Treatment Resistant Depression in Adolescents
The primary hypothesis of this study is that in fluoxetine (Prozac)-resistant adolescents with Major Depressive Disorder (MDD), Lamotrigine plus fluoxetine will be safe and as effective as sertraline (Zoloft).
- Trial name
- NCT00284791
- Testing
- Lamotrigine (drug), Fluoxetine (drug), sertraline (drug)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- MaineHealth
Major Depressive Episode, Major Depressive Disorder
Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety
This trial compares intermittent theta-burst stimulation (iTBS) to low frequency repetitive transcranial magnetic stimulation (LFR) in regards to depression and anxiety outcomes in 100 patients with treatment resistant depression…
- Trial name
- PORT (NCT05028738)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Moderate Depression, Major Depressive Disorder
Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique
The aim of this study is to explore the effectiveness and safety of different doses of neural regulation under the guidance of pBFS technology in improving symptoms in patients with moderate to severe depressive disorders.
- Conditions
- Moderate Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT06112652
- Testing
- 4 session rTMS, 6 session rTMS, 8 session rTMS
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changping Laboratory
Depression, Treatment Resistant Depression
Investigational TMS Treatment for Depression
This study is aimed to help us learn about the effects of Transcranial Magnetic Stimulation at the forehead versus the left side of the head for treatment of Treatment Resistant Depression.
- Trial name
- NCT03175887
- Testing
- TMS
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- White River Junction Veterans Affairs Medical Center
Depression
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01369095
- Testing
- Duloxetine, Escitalopram, BMS-820836
- Where
- 93 sites in United States, Argentina and 10 more
- Volunteers
- 976 people
- Sponsor
- Bristol-Myers Squibb
Depressive Disorder
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
This study will examine whether a highly specific and powerful 5-hydroxytryptamine 2A (5-HT2A) antagonist, M100907, combined with escitalopram, is responsible for an antidepressant effect.
- Trial name
- NCT00070694
- Testing
- MDL100.907
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
Translational Biomarkers in Accelerated Neuromodulation for Treatment-resistant Depression
Background: 30-50% of patients with Major Depressive Disorder (MDD) do not respond adequately despite two or more antidepressant treatments with proper dosage and timing of administration, configuring a condition of…
- Trial name
- ReModula (NCT05798143)
- Testing
- Accelerated Repetitive Transcranial Magnetic Stimulation
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- ITAB - Institute for Advanced Biomedical Technologies
Major Depressive Disorder
Ketamine in Adolescents With Treatment-Resistant Depression
This study will test the use of ketamine for treatment of depression in adolescents that have not responded to other treatments. We will also examine neurobiological mechanisms of treatment.
- Trial name
- NCT02078817
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Depression, Dementia
Longitudinal Observational Biomarker Study
The purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.
- Conditions
- Depression, Dementia, Mild Cognitive Impairment
- Trial name
- OPT-Neuro (NCT05204940)
- Testing
- Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI), Neuropsychological Data, Clinical Scales
- Where
- 5 sites in United States, Canada
- Volunteers
- 506 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder (MDD), Major Depressive Episode
Digital Interventions for Adults with Treatment-Resistant Depression: a Pilot Study
The goal of this observational study is to learn about remote mental health monitoring technology for adults with treatment-resistant depression.
- Conditions
- Major Depressive Disorder (MDD), Major Depressive Episode, Treatment-Resistant Major Depressive Disorder
- Trial name
- NCT06732089
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Unity Health Toronto
Treatment Resistant Major Depressive Disorder
DBS of the Lateral Habenula in Treatment-Resistant Depression
This research study will investigate the safety, tolerability, and benefit of bilateral deep brain stimulation (DBS) to the lateral habenula in subjects with treatment-resistant major depression (TRD) secondary to either…
- Trial name
- NCT01798407
- Testing
- Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wayne Goodman MD
Refractory Depression, Treatment Resistant Depression
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
The goal of this clinical trial is to test how well psilocybin-assisted therapy works in treating people with depression. The main questions this study aims to answer are: Does psilocybin with assisted therapy help improve…
- Trial name
- NCT06303739
- Testing
- psilocybin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Depression
Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)
The primary aims of this study are to: 1. Assess the efficacy of aripiprazole augmentation for the acute and continuation treatment of TRLLD.
- Trial name
- IRL GREY (NCT00892047)
- Testing
- venlafaxine XR plus aripiprazole
- Where
- 3 sites in United States, Canada
- Volunteers
- 468 people
- Sponsor
- University of Pittsburgh
Depression, Unipolar, Treatment Resistant Depression
PF-04995274 and Emotional Processing in Treatment Resistant Depression
This study will test whether seven days adjunctive administration of a serotonin receptor subtype 4 (5HT4) agonist called PF-04995274 has positive effects on emotional processing and non-emotional cognition in medicated…
- Trial name
- RESTART (NCT03515733)
- Testing
- PF-04995274
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- University of Oxford